Navigation Links
Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
Date:2/26/2013

tive expenses for the full year 2012 were $2.6 million, compared to $2.2 million for the full year 2011. This increase is related to professional fees and non-cash expenses for replacing previously issued warrants to Sigma-Tau upon reacquiring the rights to orBec® and accelerating the vesting of certain stock options issued to a former employee.

As of December 31, 2012, the Company's cash position was $3.4 million with working capital of $2.7 million.  

Christopher J. Schaber , PhD, President and Chief Executive Officer of Soligenix stated, "Throughout the year, we continued to make progress in advancing a number of our programs utilizing oral BDP, in both our BioTherapeutics and Vaccine/BioDefense business segments, as well as expanding our pipeline with acquired technology. In December 2012, we were successful in regaining North American and European commercial rights to oral BDP from Sigma-Tau and we expanded our pipeline with the acquisition of a novel innate defense regulator technology known as SGX94. We believe SGX94 is highly synergistic with our existing development pipeline in cancer supportive care and biodefense, and we anticipate the potential for a number of grant funding opportunities for SGX94 across both business segments."

Schaber continued, "In January, we were pleased to receive an invitation from the Biomedical Advanced Research and Development Authority (BARDA) to submit a contract proposal for the development of OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS), which was submitted in February.  We are also pleased with the momentum we have built entering 2013, and are excited about the opportunities we see in both of our business segments. I look forward to reporting on our progress on all programs throughout the coming year."

Soligenix's Recent Highlights:


    SOURCE Soligenix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
    2. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
    3. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
    (Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
    (Date:8/30/2014)... The Global and China Electrical Insulating ... on the current state of the Electrical Insulating ... report provides a basic overview of the industry, ... market analysis and Chinese domestic market analysis are ... and competitive landscape of the market. A comparison ...
    (Date:8/29/2014)... of the most promising technologies for future quantum circuits ... instead of electrons. First, it is necessary to be ... control their direction. Researchers around the world have made ... now scientists at the Niels Bohr Institute have succeeded ... at a time and in a particular direction. The ...
    Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
    ... 11 AtriCure, Inc.,(Nasdaq: ATRC ), a ... surgical,ablation products, today announced that the first patient ... Richard Kaplon, a,well-known cardiac surgeon, performed the procedure ... purpose of the ABLATE clinical trial is to ...
    ... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
    ... Ltd. announced that the,quantitative analysis of Replikin Count(TM) ... H5N1 cycle is over. Sporadic outbreaks may,continue, but ... expected to subside - until the next rapid ... begins., 140,000 virus protein sequences were analyzed ...
    Cached Biology Technology:AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2
    (Date:9/1/2014)... The week-long discussions and decisions of the Nomenclature Section ... Melbourne, Australia in July 2011. This meeting is held ... premier experts on the rules for naming algae, fungi ... rule book for naming the organisms they study. This ... Code of Nomenclature for algae, fungi, and plants, which ...
    (Date:8/31/2014)... bacteria C. diff , that causes diarrhoea, temperature ... at the University of Leicester. , Using a mass ... possible to identify the unique ,smell, of C. ... the condition., What is more, the Leicester team say ... the disease simply from their smell a chemical ...
    (Date:8/31/2014)... the last 19 years reveals that fresh water from melting ... to rise by 2cm more than the global average of ... rapid rise in sea-level by studying satellite scans of a ... , The melting of the Antarctic ice sheet and ... of around 350 gigatonnes of freshwater to the surrounding ocean. ...
    Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
    ... been inspiring debate across the scientific community since the ... wider discussion about open access publishing has advanced to ... its first few articles (please see http://f1000research.com/articles ). ... further articles will be published on the current consultation ...
    ... have long known that the body rids itself of excess ... liver and excreting them through the liver,s bile. However, a ... 22 in PLoS ONE suggests that when this ... A molecule sequesters only that mineral and routes it from ...
    ... new genetic mutation that causes familial amyotrophic lateral sclerosis ... Gehrig,s Disease, has been identified by a team of ... Medical School (UMMS). Mutations to the profilin (PFN1) gene, ... nerve cell axons, is estimated to account for one ...
    Cached Biology News:First articles now live on F1000 Research 2First articles now live on F1000 Research 3Copper's previously unknown exit strategy 2Copper's previously unknown exit strategy 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3